Inhaled Nitric Oxide Market Size, Share and Growth Forecast 2025-2033
Rohit Pujari
Market Overview:
The Inhaled Nitric Oxide Market is experiencing steady expansion, driven by Growing Prevalence of Respiratory Diseases in Newborns, Rising Geriatric Population and Increasing Investments in Advanced Healthcare Infrastructure. According to IMARC Group's latest research publication, "Inhaled Nitric Oxide Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025–2033", The global inhaled nitric oxide market size was valued at USD 1,002.83 Million in 2024. Looking forward, IMARC Group estimates the market to reach USD 1,732.93 Million by 2033, exhibiting a CAGR of 5.64% from 2025-2033.
This detailed analysis primarily encompasses industry size, business trends, market share, key growth factors, and regional forecasts. The report offers a comprehensive overview and integrates research findings, market assessments, and data from different sources. It also includes pivotal market dynamics like drivers and challenges, while also highlighting growth opportunities, financial insights, technological improvements, emerging trends, and innovations. Besides this, the report provides regional market evaluation, along with a competitive landscape analysis.
Download a sample PDF of this report: https://www.imarcgroup.com/inhaled-nitric-oxide-market/requestsample
Our Report Includes:
Market Dynamics
Market Trends and Outlook
Competitive Analysis
Industry Segmentation
Strategic Recommendations
Growth Factors in the Inhaled Nitric Oxide Industry:
Growing Prevalence of Respiratory Diseases in Newborns
Respiratory and other diseases increasingly prevail in neonates, and this mainly factors into the inhaled nitric oxide (iNO) market's growing. Inhaled nitric oxide therapy is needed for premature neonates that have hypoxic respiratory failure and persistent pulmonary hypertension when conventional therapy does not work. Nitric oxide can help maximize the oxygen levels within the blood, thereby decreasing the use of ECMO. Worldwide, the National Institutes of Health (NIH) estimate that the lower respiratory infections in children aged under 5 years would cause 37.8 million cases, with 501,910 deaths and 44.8 million disability-adjusted life years (DALYs) annually. As the incidence of premature birth has increased, so too have the number of hospitals and NICUs that use the therapy. Other licenses and clinical pathways have expanded use of iNO in NICUs. The use of iNO is increasing as health systems become better able to afford it and use it.
Rising Geriatric Population
The increasing geriatric population drives the inhaled nitric oxide market growth. Older adults are at high risk for hypertension, atherosclerosis, peripheral artery disease, heart failure, and thrombosis inhaled NO is the preferred vasodilator. MDPI's 2024 report states that the proportion of heart failure patients grows with age, from 1% in patients younger than 55 years, to more than 10% in patients older than 70 years. Other diseases with increased incidence in the older age group include COPD, pulmonary hypertension and ARDS, which all respond well to oxygen therapy. Inhaled nitric oxide (iNO) is an option for older patients as it increases oxygen flow and reduces lung pressure. As life expectancy increases the healthcare system must adapt to continue to provide care for people with this condition.
Increasing Investments in Advanced Healthcare Infrastructure
Increased investment in advanced healthcare infrastructure will strengthen inhaled nitric oxide market growth. As per the official website of the International Trade Administration (ITA), India launched 5 new All India Institute of Medical Sciences (AIIMS) centers and 202 healthcare infrastructure projects in various states across India in 2024 to increase healthcare technology advancements and developments. Since inhaled nitric oxide requires a specialized high-technology gas delivery system, centers that can deliver nitric oxide are typically those that have a neonatal intensive care unit, specialized neonatal care unit, or a modern intensive care unit with specialized equipment to treat hypoxic respiratory failure, pulmonary hypertension, and ARDS in both newborns and adults.
Key Trends in the Inhaled Nitric Oxide Market
Emergence of AI-Integrated Respiratory Monitoring Systems
AI is being used to optimize inhaled nitric oxide delivery. AI delivery devices employ machine learning plus patient data. They automatically adjust the inhaled nitric oxide dose. This adjustment minimizes adverse effects. It also improves clinical outcomes. Healthcare professionals could then intervene early. They would use predictive analytics. This would anticipate changes in oxygen saturation levels. Companies are developing cloud-based inhalation devices toward remote patient monitoring and management. So hospitals use these smart devices to ensure that patients are treated properly and not readmitted toward integrating respiratory therapy with digital health technologies to improve safety for patients.
Adoption of Eco-Friendly and Sustainable Gas Delivery Technologies
Sustainability prioritizes the inhaled nitric oxide market, and manufacturers work on developing delivery devices that generate less electronic waste and gas emissions. These new-generation devices feature on-demand nitric oxide generation technology, with reduction of the need for pressurized nitric oxide gas cylinders, improving the environmental footprint and logistics. Manufacturers invest to recycle and to use energy efficiently during production for international sustainability targets. Hospitals investing in green medical technology want compact eco-friendly technology. It must have good clinical efficacy and minimize its environmental impact.
Growing Clinical Trials for Expanded Therapeutic Applications
Clinical trials increase not only in newborn and lung disease, but also investigate other potential indications, such as acute respiratory distress syndrome (ARDS), post-cardiac surgery complications and as an adjunctive treatment in infectious diseases, particularly for lung injury related to COVID-19 infection. Pharmaceutical partnerships with academic institutions also are testing the use of nitric oxide as an anti-inflammatory and vasodilator for other indications, in addition. As clinicians experience the drug more, the number of indications may expand, creating meaningful incremental opportunities to use it for critical care and outpatient respiratory issues.
Leading Companies Operating in the Global Inhaled Nitric Oxide Industry:
Air Liquide S.A
Bellerophon Therapeutics
Beyond Air Inc.
Linde plc
Mallinckrodt plc
Merck KGaA
Novoteris LLC
Nu-Med Plus
VERO Biotech LLC
Inhaled Nitric Oxide Market Report Segmentation:
Breakup by Application:
Neonatal Respiratory Treatment
Chronic Obstructive Pulmonary Disease (COPD)
Acute Respiratory Distress Syndrome (ARDS)
Others
Neonatal respiratory treatment held 86.1% of the market share in 2024 as it is the primary therapy for newborns with hypoxic respiratory failure and persistent pulmonary hypertension.
Breakup by Region:
North America (United States, Canada)
Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
Latin America (Brazil, Mexico, Others)
Middle East and Africa
North America, accounting for 77.7%, enjoys the leading position in the market due to strong healthcare infrastructure, high prevalence of respiratory diseases, advanced research, and favorable regulatory policies.
Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sa...@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1–201971–6302